CA2007896A1 - Method of treating hypertension using a thromboxane a2 receptor antagonist and new combinations - Google Patents
Method of treating hypertension using a thromboxane a2 receptor antagonist and new combinationsInfo
- Publication number
- CA2007896A1 CA2007896A1 CA002007896A CA2007896A CA2007896A1 CA 2007896 A1 CA2007896 A1 CA 2007896A1 CA 002007896 A CA002007896 A CA 002007896A CA 2007896 A CA2007896 A CA 2007896A CA 2007896 A1 CA2007896 A1 CA 2007896A1
- Authority
- CA
- Canada
- Prior art keywords
- thromboxane
- receptor antagonist
- alpha
- lower alkyl
- aryl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 239000003769 thromboxane A2 receptor blocking agent Substances 0.000 title claims abstract description 29
- 229940123987 Thromboxane A2 receptor antagonist Drugs 0.000 title claims abstract description 26
- 206010020772 Hypertension Diseases 0.000 title claims abstract description 23
- 238000000034 method Methods 0.000 title claims abstract description 23
- -1 7-oxabicycloheptane prostaglandin Chemical class 0.000 claims abstract description 36
- 239000002876 beta blocker Substances 0.000 claims abstract description 10
- 229940097320 beta blocking agent Drugs 0.000 claims abstract description 10
- 239000002934 diuretic Substances 0.000 claims abstract description 9
- 230000001882 diuretic effect Effects 0.000 claims abstract description 8
- 229940124143 Endopeptidase inhibitor Drugs 0.000 claims abstract description 6
- 101500027325 Homo sapiens Atrial natriuretic peptide Proteins 0.000 claims abstract description 6
- 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 claims abstract description 6
- 239000005541 ACE inhibitor Substances 0.000 claims abstract description 5
- 101710129690 Angiotensin-converting enzyme inhibitor Proteins 0.000 claims abstract 4
- 101710086378 Bradykinin-potentiating and C-type natriuretic peptides Proteins 0.000 claims abstract 4
- 125000000217 alkyl group Chemical group 0.000 claims description 31
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 23
- 239000002396 thromboxane receptor blocking agent Substances 0.000 claims description 18
- 125000003118 aryl group Chemical group 0.000 claims description 14
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 12
- DYWAPFDKPAHSED-UHFFFAOYSA-N 2-cycloheptyloxepane Chemical group C1CCCCCC1C1OCCCCC1 DYWAPFDKPAHSED-UHFFFAOYSA-N 0.000 claims description 11
- 229940122202 Thromboxane receptor antagonist Drugs 0.000 claims description 11
- 125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 claims description 10
- 125000003545 alkoxy group Chemical group 0.000 claims description 10
- 125000003710 aryl alkyl group Chemical group 0.000 claims description 8
- 229940127291 Calcium channel antagonist Drugs 0.000 claims description 6
- 239000000480 calcium channel blocker Substances 0.000 claims description 6
- AQHHHDLHHXJYJD-UHFFFAOYSA-N propranolol Chemical compound C1=CC=C2C(OCC(O)CNC(C)C)=CC=CC2=C1 AQHHHDLHHXJYJD-UHFFFAOYSA-N 0.000 claims description 6
- 125000004356 hydroxy functional group Chemical group O* 0.000 claims description 5
- 125000004076 pyridyl group Chemical group 0.000 claims description 5
- 125000003342 alkenyl group Chemical group 0.000 claims description 4
- 125000003282 alkyl amino group Chemical group 0.000 claims description 4
- 125000000304 alkynyl group Chemical group 0.000 claims description 4
- 125000001691 aryl alkyl amino group Chemical group 0.000 claims description 4
- 125000001769 aryl amino group Chemical group 0.000 claims description 4
- 125000004104 aryloxy group Chemical group 0.000 claims description 4
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 claims description 4
- 241000894007 species Species 0.000 claims description 4
- 125000001544 thienyl group Chemical group 0.000 claims description 4
- IFYLTXNCFVRALQ-OALUTQOASA-N Ceronapril Chemical compound O([C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(O)=O)P(O)(=O)CCCCC1=CC=CC=C1 IFYLTXNCFVRALQ-OALUTQOASA-N 0.000 claims description 3
- 108010061435 Enalapril Proteins 0.000 claims description 3
- 108010007859 Lisinopril Proteins 0.000 claims description 3
- 230000036772 blood pressure Effects 0.000 claims description 3
- FAKRSMQSSFJEIM-RQJHMYQMSA-N captopril Chemical group SC[C@@H](C)C(=O)N1CCC[C@H]1C(O)=O FAKRSMQSSFJEIM-RQJHMYQMSA-N 0.000 claims description 3
- 229960000830 captopril Drugs 0.000 claims description 3
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims description 3
- GBXSMTUPTTWBMN-XIRDDKMYSA-N enalapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(O)=O)CC1=CC=CC=C1 GBXSMTUPTTWBMN-XIRDDKMYSA-N 0.000 claims description 3
- 229960000873 enalapril Drugs 0.000 claims description 3
- 229960002490 fosinopril Drugs 0.000 claims description 3
- 125000000717 hydrazino group Chemical group [H]N([*])N([H])[H] 0.000 claims description 3
- 229960002394 lisinopril Drugs 0.000 claims description 3
- RLAWWYSOJDYHDC-BZSNNMDCSA-N lisinopril Chemical compound C([C@H](N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(O)=O)C(O)=O)CC1=CC=CC=C1 RLAWWYSOJDYHDC-BZSNNMDCSA-N 0.000 claims description 3
- 229960004255 nadolol Drugs 0.000 claims description 3
- VWPOSFSPZNDTMJ-UCWKZMIHSA-N nadolol Chemical group C1[C@@H](O)[C@@H](O)CC2=C1C=CC=C2OCC(O)CNC(C)(C)C VWPOSFSPZNDTMJ-UCWKZMIHSA-N 0.000 claims description 3
- 229960003712 propranolol Drugs 0.000 claims description 3
- 150000003839 salts Chemical class 0.000 claims description 3
- 229940124549 vasodilator Drugs 0.000 claims description 3
- 239000003071 vasodilator agent Substances 0.000 claims description 3
- IAIDUHCBNLFXEF-MNEFBYGVSA-N zofenopril Chemical compound C([C@@H](C)C(=O)N1[C@@H](C[C@@H](C1)SC=1C=CC=CC=1)C(O)=O)SC(=O)C1=CC=CC=C1 IAIDUHCBNLFXEF-MNEFBYGVSA-N 0.000 claims description 3
- 229960002769 zofenopril Drugs 0.000 claims description 3
- BIDNLKIUORFRQP-XYGFDPSESA-N (2s,4s)-4-cyclohexyl-1-[2-[[(1s)-2-methyl-1-propanoyloxypropoxy]-(4-phenylbutyl)phosphoryl]acetyl]pyrrolidine-2-carboxylic acid Chemical compound C([P@@](=O)(O[C@H](OC(=O)CC)C(C)C)CC(=O)N1[C@@H](C[C@H](C1)C1CCCCC1)C(O)=O)CCCC1=CC=CC=C1 BIDNLKIUORFRQP-XYGFDPSESA-N 0.000 claims description 2
- METKIMKYRPQLGS-GFCCVEGCSA-N (R)-atenolol Chemical compound CC(C)NC[C@@H](O)COC1=CC=C(CC(N)=O)C=C1 METKIMKYRPQLGS-GFCCVEGCSA-N 0.000 claims description 2
- 229910052783 alkali metal Inorganic materials 0.000 claims description 2
- 125000004183 alkoxy alkyl group Chemical group 0.000 claims description 2
- 125000000278 alkyl amino alkyl group Chemical group 0.000 claims description 2
- 125000005127 aryl alkoxy alkyl group Chemical group 0.000 claims description 2
- 125000005128 aryl amino alkyl group Chemical group 0.000 claims description 2
- 125000005160 aryl oxy alkyl group Chemical group 0.000 claims description 2
- 229960002274 atenolol Drugs 0.000 claims description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 2
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 2
- HRDXJKGNWSUIBT-UHFFFAOYSA-N methoxybenzene Chemical group [CH2]OC1=CC=CC=C1 HRDXJKGNWSUIBT-UHFFFAOYSA-N 0.000 claims description 2
- 125000000547 substituted alkyl group Chemical group 0.000 claims description 2
- 150000003536 tetrazoles Chemical class 0.000 claims description 2
- TWBNMYSKRDRHAT-RCWTXCDDSA-N (S)-timolol hemihydrate Chemical compound O.CC(C)(C)NC[C@H](O)COC1=NSN=C1N1CCOCC1.CC(C)(C)NC[C@H](O)COC1=NSN=C1N1CCOCC1 TWBNMYSKRDRHAT-RCWTXCDDSA-N 0.000 claims 1
- SGUAFYQXFOLMHL-UHFFFAOYSA-N 2-hydroxy-5-{1-hydroxy-2-[(4-phenylbutan-2-yl)amino]ethyl}benzamide Chemical compound C=1C=C(O)C(C(N)=O)=CC=1C(O)CNC(C)CCC1=CC=CC=C1 SGUAFYQXFOLMHL-UHFFFAOYSA-N 0.000 claims 1
- 229960002122 acebutolol Drugs 0.000 claims 1
- GOEMGAFJFRBGGG-UHFFFAOYSA-N acebutolol Chemical compound CCCC(=O)NC1=CC=C(OCC(O)CNC(C)C)C(C(C)=O)=C1 GOEMGAFJFRBGGG-UHFFFAOYSA-N 0.000 claims 1
- 125000002102 aryl alkyloxo group Chemical group 0.000 claims 1
- 229960001632 labetalol Drugs 0.000 claims 1
- 229960004605 timolol Drugs 0.000 claims 1
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 16
- 239000005557 antagonist Substances 0.000 description 15
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 12
- 239000000203 mixture Substances 0.000 description 11
- 235000019359 magnesium stearate Nutrition 0.000 description 8
- 238000009472 formulation Methods 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- RZWIIPASKMUIAC-VQTJNVASSA-N thromboxane Chemical compound CCCCCCCC[C@H]1OCCC[C@@H]1CCCCCCC RZWIIPASKMUIAC-VQTJNVASSA-N 0.000 description 7
- DSNBHJFQCNUKMA-SCKDECHMSA-N thromboxane A2 Chemical compound OC(=O)CCC\C=C/C[C@@H]1[C@@H](/C=C/[C@@H](O)CCCCC)O[C@@H]2O[C@H]1C2 DSNBHJFQCNUKMA-SCKDECHMSA-N 0.000 description 7
- 229920002261 Corn starch Polymers 0.000 description 6
- 102000003938 Thromboxane Receptors Human genes 0.000 description 6
- 108090000300 Thromboxane Receptors Proteins 0.000 description 6
- 239000004480 active ingredient Substances 0.000 description 6
- 239000008120 corn starch Substances 0.000 description 6
- 239000002464 receptor antagonist Substances 0.000 description 6
- 229940044551 receptor antagonist Drugs 0.000 description 6
- 239000011780 sodium chloride Substances 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 108010010803 Gelatin Proteins 0.000 description 5
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 5
- 229920000159 gelatin Polymers 0.000 description 5
- 239000008273 gelatin Substances 0.000 description 5
- 235000019322 gelatine Nutrition 0.000 description 5
- 235000011852 gelatine desserts Nutrition 0.000 description 5
- QELSKZZBTMNZEB-UHFFFAOYSA-N p-hydroxybenzoic acid propyl ester Natural products CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 5
- 229940068196 placebo Drugs 0.000 description 5
- 239000000902 placebo Substances 0.000 description 5
- 239000008215 water for injection Substances 0.000 description 5
- HSUGRBWQSSZJOP-RTWAWAEBSA-N diltiazem Chemical compound C1=CC(OC)=CC=C1[C@H]1[C@@H](OC(C)=O)C(=O)N(CCN(C)C)C2=CC=CC=C2S1 HSUGRBWQSSZJOP-RTWAWAEBSA-N 0.000 description 4
- 229960004166 diltiazem Drugs 0.000 description 4
- 239000004615 ingredient Substances 0.000 description 4
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 229940102223 injectable solution Drugs 0.000 description 3
- 150000002500 ions Chemical class 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 229940016286 microcrystalline cellulose Drugs 0.000 description 3
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 3
- 239000008108 microcrystalline cellulose Substances 0.000 description 3
- 239000003755 preservative agent Substances 0.000 description 3
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 3
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 3
- 229960003415 propylparaben Drugs 0.000 description 3
- UUUHXMGGBIUAPW-UHFFFAOYSA-N 1-[1-[2-[[5-amino-2-[[1-[5-(diaminomethylideneamino)-2-[[1-[3-(1h-indol-3-yl)-2-[(5-oxopyrrolidine-2-carbonyl)amino]propanoyl]pyrrolidine-2-carbonyl]amino]pentanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-methylpentanoyl]pyrrolidine-2-carbon Chemical compound C1CCC(C(=O)N2C(CCC2)C(O)=O)N1C(=O)C(C(C)CC)NC(=O)C(CCC(N)=O)NC(=O)C1CCCN1C(=O)C(CCCN=C(N)N)NC(=O)C1CCCN1C(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C1CCC(=O)N1 UUUHXMGGBIUAPW-UHFFFAOYSA-N 0.000 description 2
- YURNCBVQZBJDAJ-UHFFFAOYSA-N 2-heptenoic acid Chemical compound CCCCC=CC(O)=O YURNCBVQZBJDAJ-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 102000003922 Calcium Channels Human genes 0.000 description 2
- 108090000312 Calcium Channels Proteins 0.000 description 2
- JZUFKLXOESDKRF-UHFFFAOYSA-N Chlorothiazide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC2=C1NCNS2(=O)=O JZUFKLXOESDKRF-UHFFFAOYSA-N 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical class Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 102000004270 Peptidyl-Dipeptidase A Human genes 0.000 description 2
- 108090000882 Peptidyl-Dipeptidase A Proteins 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 230000000740 bleeding effect Effects 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 150000001735 carboxylic acids Chemical class 0.000 description 2
- GKTWGGQPFAXNFI-HNNXBMFYSA-N clopidogrel Chemical compound C1([C@H](N2CC=3C=CSC=3CC2)C(=O)OC)=CC=CC=C1Cl GKTWGGQPFAXNFI-HNNXBMFYSA-N 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 230000003205 diastolic effect Effects 0.000 description 2
- 238000005469 granulation Methods 0.000 description 2
- 230000003179 granulation Effects 0.000 description 2
- 125000001475 halogen functional group Chemical group 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 2
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 2
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 description 2
- 229960002216 methylparaben Drugs 0.000 description 2
- 230000003285 pharmacodynamic effect Effects 0.000 description 2
- LCPDWSOZIOUXRV-UHFFFAOYSA-N phenoxyacetic acid Chemical compound OC(=O)COC1=CC=CC=C1 LCPDWSOZIOUXRV-UHFFFAOYSA-N 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- PVHUJELLJLJGLN-INIZCTEOSA-N (S)-nitrendipine Chemical compound CCOC(=O)C1=C(C)NC(C)=C(C(=O)OC)[C@@H]1C1=CC=CC([N+]([O-])=O)=C1 PVHUJELLJLJGLN-INIZCTEOSA-N 0.000 description 1
- WLRMANUAADYWEA-NWASOUNVSA-N (S)-timolol maleate Chemical compound OC(=O)\C=C/C(O)=O.CC(C)(C)NC[C@H](O)COC1=NSN=C1N1CCOCC1 WLRMANUAADYWEA-NWASOUNVSA-N 0.000 description 1
- SGTNSNPWRIOYBX-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile Chemical compound C1=C(OC)C(OC)=CC=C1CCN(C)CCCC(C#N)(C(C)C)C1=CC=C(OC)C(OC)=C1 SGTNSNPWRIOYBX-UHFFFAOYSA-N 0.000 description 1
- VLMZAUCKMYJSGM-UHFFFAOYSA-N 2-[4-[3-(4-chlorophenyl)sulfonylpropyl]phenyl]acetic acid Chemical compound C1=CC(CC(=O)O)=CC=C1CCCS(=O)(=O)C1=CC=C(Cl)C=C1 VLMZAUCKMYJSGM-UHFFFAOYSA-N 0.000 description 1
- WLJVXDMOQOGPHL-PPJXEINESA-N 2-phenylacetic acid Chemical compound O[14C](=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-PPJXEINESA-N 0.000 description 1
- UIAGMCDKSXEBJQ-IBGZPJMESA-N 3-o-(2-methoxyethyl) 5-o-propan-2-yl (4s)-2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate Chemical compound COCCOC(=O)C1=C(C)NC(C)=C(C(=O)OC(C)C)[C@H]1C1=CC=CC([N+]([O-])=O)=C1 UIAGMCDKSXEBJQ-IBGZPJMESA-N 0.000 description 1
- ZWAVGFSZMACJHA-PMNBYGLBSA-N 7-[2-Trifluoromethyl-4-(2-hydroxyphenyl)-1,3-dioxan-cis-5-yl]-hept-5z-enoic acid Chemical compound OC(=O)CCC\C=C/C[C@@H]1CO[C@H](C(F)(F)F)O[C@@H]1C1=CC=CC=C1O ZWAVGFSZMACJHA-PMNBYGLBSA-N 0.000 description 1
- 102000015427 Angiotensins Human genes 0.000 description 1
- 108010064733 Angiotensins Proteins 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- WQVZLXWQESQGIF-UHFFFAOYSA-N Labetalol hydrochloride Chemical compound Cl.C=1C=C(O)C(C(N)=O)=CC=1C(O)CNC(C)CCC1=CC=CC=C1 WQVZLXWQESQGIF-UHFFFAOYSA-N 0.000 description 1
- OZYUPQUCAUTOBP-QXAKKESOSA-N Levallorphan Chemical compound C([C@H]12)CCC[C@@]11CCN(CC=C)[C@@H]2CC2=CC=C(O)C=C21 OZYUPQUCAUTOBP-QXAKKESOSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 229920003091 Methocel™ Polymers 0.000 description 1
- 241001024304 Mino Species 0.000 description 1
- ZFMITUMMTDLWHR-UHFFFAOYSA-N Minoxidil Chemical compound NC1=[N+]([O-])C(N)=CC(N2CCCCC2)=N1 ZFMITUMMTDLWHR-UHFFFAOYSA-N 0.000 description 1
- CYLWJCABXYDINA-UHFFFAOYSA-N Polythiazide Polymers ClC1=C(S(N)(=O)=O)C=C2S(=O)(=O)N(C)C(CSCC(F)(F)F)NC2=C1 CYLWJCABXYDINA-UHFFFAOYSA-N 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 1
- 229940099508 TP receptor antagonist Drugs 0.000 description 1
- 101150100032 Tbxa2r gene Proteins 0.000 description 1
- DHXVGJBLRPWPCS-UHFFFAOYSA-N Tetrahydropyran Chemical compound C1CCOCC1 DHXVGJBLRPWPCS-UHFFFAOYSA-N 0.000 description 1
- FNYLWPVRPXGIIP-UHFFFAOYSA-N Triamterene Chemical compound NC1=NC2=NC(N)=NC(N)=C2N=C1C1=CC=CC=C1 FNYLWPVRPXGIIP-UHFFFAOYSA-N 0.000 description 1
- NQPDZGIKBAWPEJ-UHFFFAOYSA-N Valeric acid Natural products CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- 239000000670 adrenergic alpha-2 receptor antagonist Substances 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- BHELZAPQIKSEDF-UHFFFAOYSA-N allyl bromide Chemical compound BrCC=C BHELZAPQIKSEDF-UHFFFAOYSA-N 0.000 description 1
- XSDQTOBWRPYKKA-UHFFFAOYSA-N amiloride Chemical compound NC(=N)NC(=O)C1=NC(Cl)=C(N)N=C1N XSDQTOBWRPYKKA-UHFFFAOYSA-N 0.000 description 1
- 229960002576 amiloride Drugs 0.000 description 1
- 125000002490 anilino group Chemical group [H]N(*)C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229960003515 bendroflumethiazide Drugs 0.000 description 1
- HDWIHXWEUNVBIY-UHFFFAOYSA-N bendroflumethiazidum Chemical compound C1=C(C(F)(F)F)C(S(=O)(=O)N)=CC(S(N2)(=O)=O)=C1NC2CC1=CC=CC=C1 HDWIHXWEUNVBIY-UHFFFAOYSA-N 0.000 description 1
- 150000008038 benzoazepines Chemical class 0.000 description 1
- 150000007657 benzothiazepines Chemical class 0.000 description 1
- 229960001541 benzthiazide Drugs 0.000 description 1
- NDTSRXAMMQDVSW-UHFFFAOYSA-N benzthiazide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(S(N2)(=O)=O)=C1N=C2CSCC1=CC=CC=C1 NDTSRXAMMQDVSW-UHFFFAOYSA-N 0.000 description 1
- 235000010290 biphenyl Nutrition 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000004067 bulking agent Substances 0.000 description 1
- MAEIEVLCKWDQJH-UHFFFAOYSA-N bumetanide Chemical compound CCCCNC1=CC(C(O)=O)=CC(S(N)(=O)=O)=C1OC1=CC=CC=C1 MAEIEVLCKWDQJH-UHFFFAOYSA-N 0.000 description 1
- 229960004064 bumetanide Drugs 0.000 description 1
- 229940085822 captopril 50 mg Drugs 0.000 description 1
- 239000012876 carrier material Substances 0.000 description 1
- 229960002155 chlorothiazide Drugs 0.000 description 1
- JIVPVXMEBJLZRO-UHFFFAOYSA-N chlorthalidone Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C2(O)C3=CC=CC=C3C(=O)N2)=C1 JIVPVXMEBJLZRO-UHFFFAOYSA-N 0.000 description 1
- 239000013066 combination product Substances 0.000 description 1
- 229940127555 combination product Drugs 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- KPSZWAJWFMFMFF-UHFFFAOYSA-N delta-Hexylen-alpha-carbonsaeure Natural products CC=CCCCC(O)=O KPSZWAJWFMFMFF-UHFFFAOYSA-N 0.000 description 1
- KPSZWAJWFMFMFF-NSCUHMNNSA-N delta-heptenoic acid Chemical compound C\C=C\CCCC(O)=O KPSZWAJWFMFMFF-NSCUHMNNSA-N 0.000 description 1
- 125000004925 dihydropyridyl group Chemical group N1(CC=CC=C1)* 0.000 description 1
- 229940030606 diuretics Drugs 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000002792 enkephalinase inhibitor Substances 0.000 description 1
- 239000002532 enzyme inhibitor Substances 0.000 description 1
- 229940125532 enzyme inhibitor Drugs 0.000 description 1
- 229960003199 etacrynic acid Drugs 0.000 description 1
- AVOLMBLBETYQHX-UHFFFAOYSA-N etacrynic acid Chemical compound CCC(=C)C(=O)C1=CC=C(OCC(O)=O)C(Cl)=C1Cl AVOLMBLBETYQHX-UHFFFAOYSA-N 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- RGUQWGXAYZNLMI-UHFFFAOYSA-N flumethiazide Chemical compound C1=C(C(F)(F)F)C(S(=O)(=O)N)=CC2=C1NC=NS2(=O)=O RGUQWGXAYZNLMI-UHFFFAOYSA-N 0.000 description 1
- 229960003028 flumethiazide Drugs 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 229960002003 hydrochlorothiazide Drugs 0.000 description 1
- 229960003313 hydroflumethiazide Drugs 0.000 description 1
- DMDGGSIALPNSEE-UHFFFAOYSA-N hydroflumethiazide Chemical compound C1=C(C(F)(F)F)C(S(=O)(=O)N)=CC2=C1NCNS2(=O)=O DMDGGSIALPNSEE-UHFFFAOYSA-N 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 229960003091 labetalol hydrochloride Drugs 0.000 description 1
- 229960000263 levallorphan Drugs 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 229960001300 metoprolol tartrate Drugs 0.000 description 1
- 229960003632 minoxidil Drugs 0.000 description 1
- 229960001597 nifedipine Drugs 0.000 description 1
- HYIMSNHJOBLJNT-UHFFFAOYSA-N nifedipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1[N+]([O-])=O HYIMSNHJOBLJNT-UHFFFAOYSA-N 0.000 description 1
- 229960000715 nimodipine Drugs 0.000 description 1
- 229960005425 nitrendipine Drugs 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- HUPQYPMULVBQDL-UHFFFAOYSA-N pentanoic acid Chemical compound CCCCC(O)=O.CCCCC(O)=O HUPQYPMULVBQDL-UHFFFAOYSA-N 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 125000005359 phenoxyalkyl group Chemical group 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N phenylbenzene Natural products C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 1
- 125000005328 phosphinyl group Chemical group [PH2](=O)* 0.000 description 1
- 229960005483 polythiazide Drugs 0.000 description 1
- 229920000046 polythiazide Polymers 0.000 description 1
- 229960002429 proline Drugs 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 description 1
- LXMSZDCAJNLERA-ZHYRCANASA-N spironolactone Chemical compound C([C@@H]1[C@]2(C)CC[C@@H]3[C@@]4(C)CCC(=O)C=C4C[C@H]([C@@H]13)SC(=O)C)C[C@@]21CCC(=O)O1 LXMSZDCAJNLERA-ZHYRCANASA-N 0.000 description 1
- 229960002256 spironolactone Drugs 0.000 description 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- WUBVEMGCQRSBBT-UHFFFAOYSA-N tert-butyl 4-(trifluoromethylsulfonyloxy)-3,6-dihydro-2h-pyridine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCC(OS(=O)(=O)C(F)(F)F)=CC1 WUBVEMGCQRSBBT-UHFFFAOYSA-N 0.000 description 1
- 239000003451 thiazide diuretic agent Substances 0.000 description 1
- 229960005221 timolol maleate Drugs 0.000 description 1
- 229960001288 triamterene Drugs 0.000 description 1
- 229960004813 trichlormethiazide Drugs 0.000 description 1
- LMJSLTNSBFUCMU-UHFFFAOYSA-N trichlormethiazide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC2=C1NC(C(Cl)Cl)NS2(=O)=O LMJSLTNSBFUCMU-UHFFFAOYSA-N 0.000 description 1
- 229960001722 verapamil Drugs 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Abstract
Abstract METHOD OF TREATING HYPERTENSION
AND NEW COMBINATIONS
A method is provided for treating hypertension by administering a thromboxane A2 receptor antagonist which preferably is a 7-oxabicycloheptane prostaglandin analog. In addition, new combinations are provided containing a thromboxane A2 receptor antagonist and a beta blocker, an angiotensin converting enzyme inhibitor, a diuretic, an endopeptidase inhibitor or human ANF 99-126.
AND NEW COMBINATIONS
A method is provided for treating hypertension by administering a thromboxane A2 receptor antagonist which preferably is a 7-oxabicycloheptane prostaglandin analog. In addition, new combinations are provided containing a thromboxane A2 receptor antagonist and a beta blocker, an angiotensin converting enzyme inhibitor, a diuretic, an endopeptidase inhibitor or human ANF 99-126.
Description
20~B96 ~A492 METHOD OF TREATING HYPERTENSION
USING A THRO~OXANE A2 R~3CEPTOR ANTAGONIST
AND NEW COMBINAT I O
The present invention relates to a me~lod for treating hypertension by administering a thromboxane A2 receptor antagonist, which preferably is a 7-oxabicycloheptane prostaglandin analog, and to new combinations containi~g a thromboxane A2 receptor antagonist.
In accordance with the present invention, a method is provided for treating hypertension wherein a therapeutically effective amou~t of a ` thromboxane A2 receptor antagonist is systemically administered, such as orally or parenterally, to reduce blood pressure in mammals, including humans, during the period of treatment.
In addition, in accordance with the present invention, new combinations are provided, for treating h~pertension, containing a thromboxane A2 receptor antagonist and an angiotensin converting .~ 25 enzyme inhibitor, a beta blocker, a diuretic, an endopeptidase inhibitor anCVor human ANF 99-126.
The term "thromboxane A2 receptor ~ antagonist" as employed herein includes ompounds :
. which are so called ~hromboxane A2 receptor 30 antagonists, thromboxane A2 antagonists, ~ :
.~ "' ., -thromboxane A2/prostaglandin encloperoxide ;~ antagonists, TP-receptor antagonists, or thromboxane antagonists except insofar as the compound is solely an inhibitor of thromboxane synth~sis.
Thromboxane A2 antagonists which may be employed herein are specific inhibitors of the actions of thromboxane A2 and therefore produce t~e desired ef~ect of throm~oxa~e A2 inhibition without causing other non-specific effects that ` may be undesirable.
The thromboxane A2 receptor antagonist employed herein will preferably be a 7-oxabicyclo-heptane prostaglandin analog and will include 7-oxabicycloheptane substituted diamide prosta-glandin analogs as disclosed in U.S. Patent No.
4,663,336, 7-oxabicycloheptane substitutecl amino prostaglandin analogs as disclosed in U.S. Patent No. 4,416,896 a~d 7-oxabicycloheptane prostaglandin analogs as di~closed in U.S. Patent No. 4,537,981.
; Other 7-oxabicycloheptane prostaglandin analogs may be included as will be apparent to one skilled in the art.
The 7-oxabicycloheptane substituted diamide prostaglandin analogs suitable for use herein, as disclosed in U.S. Patent No. 4,663,336, have the . formula (CH2)m~A~(CH2)n Q
< 1*/
(CH2~p-N - C-(c~2)q-N ~C-R3 O R O R O
:; :
:' ~,'.
, ,~ ' '1. ' " ' , ' '' , . .'~ ~' ' . ' , . :
~1 ' . . ' '.':, ~ ' ' , ' ' , HA~92 including all stereoisomers thereof, wherein m is 0 to 4; A is -CH-CH- or -C~2-CH~-; n is 1 ~o 5; Q is ~CH=CH-, -CH2-, IH H~alo Halo~ ~Halo -C~ CH-, -C-.
or a single bond; R is CO2H, CO2alkyl, CO2 alkali metal, C02polyhydroxyamine salt, -CH20H, : ~N -N
~ ~ or ~NR4R5 ' ~' ; wherein R4 and R5 are the same or different and are H, lower alkyl, hydroxy, lower alkoxy or aryl at least one of R4 and R5 being other than hydroxy .
a~d lower alkoxy; p is 1 to 4; Rl is H or lo~er 20 alkyl; g is 1 to 12; R2 is H or lower alkyl; and R3 is H, lower alkyl, lower alkenyl, lower : alkynyl, aryl, arylalkyl, lower alkoxy, ~-arylalkyloxy, aryloxy, amino, alkylamino, arylalkylamino, arylamino, :
(Il)n ()n' (Il)n :~
lowex alkyl-S-, aryl-S-, arylalkyl-S-, ()n (,)n (I~n aryl-S-alkyl-, alkyl-S-alkyl-, arylalkyl-i~-alkyl (wherein n' is 0, 1 or 2), alkylaminoalkyl, arylaminoalkyl, arylalkylaminoalkyl, alkoxyalkyl, aryloxyalkyl or arylalkoxyalkyl.
:
. . .
USING A THRO~OXANE A2 R~3CEPTOR ANTAGONIST
AND NEW COMBINAT I O
The present invention relates to a me~lod for treating hypertension by administering a thromboxane A2 receptor antagonist, which preferably is a 7-oxabicycloheptane prostaglandin analog, and to new combinations containi~g a thromboxane A2 receptor antagonist.
In accordance with the present invention, a method is provided for treating hypertension wherein a therapeutically effective amou~t of a ` thromboxane A2 receptor antagonist is systemically administered, such as orally or parenterally, to reduce blood pressure in mammals, including humans, during the period of treatment.
In addition, in accordance with the present invention, new combinations are provided, for treating h~pertension, containing a thromboxane A2 receptor antagonist and an angiotensin converting .~ 25 enzyme inhibitor, a beta blocker, a diuretic, an endopeptidase inhibitor anCVor human ANF 99-126.
The term "thromboxane A2 receptor ~ antagonist" as employed herein includes ompounds :
. which are so called ~hromboxane A2 receptor 30 antagonists, thromboxane A2 antagonists, ~ :
.~ "' ., -thromboxane A2/prostaglandin encloperoxide ;~ antagonists, TP-receptor antagonists, or thromboxane antagonists except insofar as the compound is solely an inhibitor of thromboxane synth~sis.
Thromboxane A2 antagonists which may be employed herein are specific inhibitors of the actions of thromboxane A2 and therefore produce t~e desired ef~ect of throm~oxa~e A2 inhibition without causing other non-specific effects that ` may be undesirable.
The thromboxane A2 receptor antagonist employed herein will preferably be a 7-oxabicyclo-heptane prostaglandin analog and will include 7-oxabicycloheptane substituted diamide prosta-glandin analogs as disclosed in U.S. Patent No.
4,663,336, 7-oxabicycloheptane substitutecl amino prostaglandin analogs as disclosed in U.S. Patent No. 4,416,896 a~d 7-oxabicycloheptane prostaglandin analogs as di~closed in U.S. Patent No. 4,537,981.
; Other 7-oxabicycloheptane prostaglandin analogs may be included as will be apparent to one skilled in the art.
The 7-oxabicycloheptane substituted diamide prostaglandin analogs suitable for use herein, as disclosed in U.S. Patent No. 4,663,336, have the . formula (CH2)m~A~(CH2)n Q
< 1*/
(CH2~p-N - C-(c~2)q-N ~C-R3 O R O R O
:; :
:' ~,'.
, ,~ ' '1. ' " ' , ' '' , . .'~ ~' ' . ' , . :
~1 ' . . ' '.':, ~ ' ' , ' ' , HA~92 including all stereoisomers thereof, wherein m is 0 to 4; A is -CH-CH- or -C~2-CH~-; n is 1 ~o 5; Q is ~CH=CH-, -CH2-, IH H~alo Halo~ ~Halo -C~ CH-, -C-.
or a single bond; R is CO2H, CO2alkyl, CO2 alkali metal, C02polyhydroxyamine salt, -CH20H, : ~N -N
~ ~ or ~NR4R5 ' ~' ; wherein R4 and R5 are the same or different and are H, lower alkyl, hydroxy, lower alkoxy or aryl at least one of R4 and R5 being other than hydroxy .
a~d lower alkoxy; p is 1 to 4; Rl is H or lo~er 20 alkyl; g is 1 to 12; R2 is H or lower alkyl; and R3 is H, lower alkyl, lower alkenyl, lower : alkynyl, aryl, arylalkyl, lower alkoxy, ~-arylalkyloxy, aryloxy, amino, alkylamino, arylalkylamino, arylamino, :
(Il)n ()n' (Il)n :~
lowex alkyl-S-, aryl-S-, arylalkyl-S-, ()n (,)n (I~n aryl-S-alkyl-, alkyl-S-alkyl-, arylalkyl-i~-alkyl (wherein n' is 0, 1 or 2), alkylaminoalkyl, arylaminoalkyl, arylalkylaminoalkyl, alkoxyalkyl, aryloxyalkyl or arylalkoxyalkyl.
:
. . .
2~7~396 _4_ ; The 7-oxabicycloheptane subs~itu~ed amino prostaglandin analogs suitable for use herein, as disclosed in U.S. Patent No. 4,416,896, have the formula ~H2-A- ( C'}~2 )ml CRa *~
~ H2 )rl ~~H~Ra and including all stereoisomers thereof, wherlein A is C~=CH or (CH2)2; m1 is 1 to 8; n1 is 0 ,! to 5, Ra is H or lower alkyl, and Ra is lower alkyl, aryl, aralkyl, lower alkoxy, aralkoxy or O
a 20 wherein R2a is lower alkyl, aryl, aralkyl, alkoxy, ~` aryloxy, aralkoxy, alkylamino, arylamino or aralkylamino.
:~ The 7-oxabicycloheptane prostaglandin analogs suitable for use herein, as disclosed in 25 U.S. Patent No. 4,537,981, have the formula ~2-A-(C~2)m -X
B-CH~Y
o OH
.
.,~
,.`~
.
, . ~ . .
., . :. . ' ' ' ' ' ' ' ' ' ' ' ' ' . . " ', .;`.~': . . , : - ' . ,, , ~ : ,. .: .. . . . :; ;:
.
~ 2t~ 7~96 ~:
_5_ and including all stereoisomers th~reof, wherein A
and B may be the same or differe~nt and A is cH=CH or (c~2)2; B is CH=CH, c--c or (~H2)2; m1 is 1 to 8;
X is OH;
N~-N
c~ il N--N
: 10 CO2Ra wherein Ra is H or lower alkyl; or ' O :
:: It CNH-Z
. wherein Z is H, lower alkyl, aryl, SO2-Q~
; (with Q1 being lower alkyl or aryl), -I~ .
C-Q , " 1 ,~ .
or O~ wherein ~ is H, and Y is alkyl, ..
;. substituted alkyl; aryl-lower alkyl; alkenyl; , ~;
alkynyl, aryl; pyridyl; substituted pyridyl; ~-20 pyridyl-lower alkyl; thienyl, substituted thienyl; :~.
thienyl-lower alkyl; cycloalkyl; cycloalkylalkyl;
substituted cycloalkylalkyl; or phenoxymethyl.
. Preferred exc~mples of thromboxane A2 receptor antagonists which may be employed herein 25 include the 7-oxabicycloheptane compounds disclosed ~ :
in U.S. Patsnt No. 4,537,981, especially, [lS-[la,2a(5Z),3a(1E,3R,~S~,4a]]-7-~3-(3-hydroxy-4-phenyl-l-pentenyl)-7-oxabicyclo-[2.2.1]hept-2-yl]-5-heptenoic acid; the 7-oxabicycloheptane :~
substituted amino-prostaglandin analog~ disclosed in U.S. Patent No. 4,416,896, especially, ~lS- :~
: [ la, 2~,(5Z),3~, 4a ~ ] - 7- [ 3 - ~ [ 2-(phenyl~mino)carbonyl]
hydrazino]methyl]-7-oxabicyclo[2.2.1]hept-2-yl]-5-. ~'.
.,~. - . .
. . .
.. . . . ,, .. . , . ~ .,. . . ,. ., :. . . . , .~- .. .
heptenoic acid; the 7-oxabicycloheptane substituted diamide prostaglandin analogs di~closed in U.S. ~.
Patent No. 4,663,336, especially, [1S-[1~,2al5Z), 3a,4~]]-7-[3-[[[[(1 oxoheptyl)amino~acetyl]amino]
; 5 methyl]-7-oxabicyclo[2.2.1]hept-.2-yl~-5-heptenoic acid and the corresponding tetrazole, and [lS-[la,2a(Z),3a,4~]]-7-[3-[[[[(4-cyclohexyl-1-; oxobutyl)amino]acetyl]amino~methyl]-7-oxabicyclo~
[2.2.1Jhept-2-yl]-5-heptenoic acid.
Examples of other such thromboxane A2 antagonists suitable for use herein include but are not limited to the phenoxyalkyl carboxylic aci.ds disclosed in U. S. Patent No. 4,258,058 to Witte et al, especially 4-[2-(benzenesulfamido)ethyl]phenoxy-: 15 acetic acid, (BM 13,177 - Boehringer Mannheim), the sulphonamidophenyl carboxylic acids disclosed in U. S. Patent No. 4,443,~77 to Witte et al, especially 4-[2-(4-chlorobenzenesulfonamido)-, ethyl]phenylacetic acid, ~BM 13,505, Boehringer Mannheim) the arylthioalkylphenyl carboxylic acids disclosed in U. S. Patent No. 4,752,676 espscially 4-(3-((4-chlorophenyl)sulfonyl)propyl)benzeneacetic acid, (E)-5-[~[(pyridinyl)[3-(trifluoro-methyl)phenyl]methylene]amino]oxy]pentanoic acid also referred to as R68,070 - Janssen Research Laboratories, 3-[1-(4-chlorophenylmethyl)-5-fluoro-3-~ethylindol-2-yl]-2,2-dimethylpropanoic acid [(L-655240 Merck-Frosst) Eur. J. Pharmacol.
135(2):193, 17 Mar. 87], 5(Z)-7-([2,4,5-cis]-4-(2-hydroxyphenylj-2-trifluoromethyl-1,3-dioxan-5-yljheptenoic acid (ICI 185282, Brit. J.
:: Pharmacol 90 (Proc. Suppl):228 P-Abs., Mar. 87), 5(Z)-7 [2,2-dimethyl-4-phenyl-1,3-dioxan-cis-5-yl3-, . . .
. ~ , . . ~
.' ' ' ',: . : " , :
' ., ' ' ., ',:. . ' . ' ' ;
.... ~
. . . . .. .
HA~92 heptenoic acid (ICI 159995~ Brit. J. Pharmacol. 86 (Proc. suppl):808 P-Abs., Dec. 85~, N,N'-bis~7-(3-chlorobenzeneaminosulfonyl)-1,2,3,4- -tetrahydro-isoquinolyl]disulfonylimide (SKF 88046, ~ 5 Pharmacologist 25(3):116 Abs, 117 Abs, Aug. 83), ; [la(Z)-2~,5a]-(+~-7-[5-[[(1,1'-biphenyl)-4-yl]-methoxy]-2-(4-morpholinyl)-3-oxocyclopentyl]-4-heptenoic acid (A~ 23848 - Glaxo, Circulation 72(6):1208, Dec. 85, levallorphan allyl bromide (CN 32,191, Sanofi, Life Sci. 31 (20-21):2261, 15 ,~
; ~ov. 82), (Z,2-endo-3-oxo)-7-(3 acetyl-2-bicyclo-[2.2.1]heptyl-5-hepta-3Z-enoic acid, 4-phenylthiosemicarbazone (EP092 - Univ.
Edinburgh, Brit, J. Pharmacol. 84(3):595, Mar. 85).
The disclosures of the above-mentioned patents are incorporated herein by reference.
In carrying out the method of the present invention, the thromboxane A2 receptor antagonist may be administered systemically, such as orally or parenterally, to mammalian species, such as monkeys, dogs, cats, rats, humans, etc.
The thromboxane A2 receptor antagonist may be incorporated in a conventional dosage form, such as a tablet, capsule, elixir or injectable.
The above dosage forms will also include the necessary carrier material, excipient, lubricant, bufer, antibacterial, bulking agent (such as mannitol), anti-oxidants (ascorbic acid or sodium bisulfite) or the like. Oral dosage forms are preferred, although parenteral forms are quite satisfactory as well.
With regard to such systemic formulations, single or divided doses of rom about 0.5 to about . ' .
: .
2~37B96 ~A492 2500 mg, preferably from about 5 to 500 mg one to six times daily, may be administered in systemic dosage forms as described above for a prolonged period, that is, for as long as hypertension continues. Sustained release forms of such ; formulations which may provide such amounts biweekly, weekly, monthly and the lik~ may also be employed.
The thromboxane antagonist can al90 be formulated with a diuretic for the treatment of hyper~ension. A combination product comprising thromboxane antagonist and a diuretic can be a~ministered in an effective amount which comprises a totally daily dosage of about 30 to 600 mg, preferably about 30 to 330 mg of thromboxane antagonist, and about 15 to 300 mg preferably about 15 to 200 of the diuretic, to a mammalian species in need thereof. Exemplary of the diuretics contemplated for use in combination with a compound of this invention are the thiazide diuretics, e.g., chlorothiazide, hydrochlorothiazide, flumethiazide, hydroflumethiazide, bendroflumethiazide, methylclo~hiazide, trichloromethiazide, polythiazide or benzthiazide as well as ethacrynic acid, tricrynafen, chlorothalidone, furosamide, musolimine, bumetanide, triamterene, amiloride and spironolactone and salts of such compounds.
In treating hyperten~ion, the thromboxane receptor antagonists may be administered in combination with an angiotensin-converting enzyme (ACE) inhibitor such as captopril, zofenopril, - fosinopril, enalapril, lisinopril, (S)~1-[6-amino-~ .
- :," ~, " , . ,:
, , : ; , .
2~ 396 _ 9~
2-[[hydroxy(4-phenylbutyl)phosphinyl]oxy]-1-oxohexyl]-L-proline (SQ 29,852) etc. employing the ACE inhibitor in an amount as indicated in the Physicians Desk Reference (PDR), for example, from about 5 to about 350 mg per day. Such combination would be at a weight ratio of thromboxane antago~ist to ACE i~libitor of from about 1:1~ t~ about 10:1.
; The thromboxane receptor antagonists can ; 10 also be administered in combination with a neutral endopeptidase inhibitor or with human ANF 99 -126 in treating hypertension. Such combination would contain the ~hromboxane antagonist at from about 1 to about 500 mg per day and an endopepti-dase inhibitor of from about 1 to about 100 mg per kg of body weight or the human ANF 99 - 126 at from about 0.001 to about 0.1 mg per kg of body weight.
In addition, in treating hypertension, the thromboxane receptor antagonists may be employed in combination with a beta blocker such as propranolol, ~adolol, timolol maleate, metoprolol tartrate, labetalol hydrochloride and the like employing ~he beta blocker in amounts as indicated in the PDR such as in an amount of from about 5 to about 350 mg per day. Such a combination would be at a weight ratio of thromboxane antagonist to beta blocker of from about l:lO to about 10:1.
The thromboxane receptor antagonist, in treating hypertension, may also be used in combination with a calcium channel blocker such as dihydropyridines such as niedipine, nitrendipine, nimodipine, phenylalkylamines such as verapamil, benzothiazepines such as diltiazem and ., .
.. , ' '' ~ . . . ., ;. . : . .. ..
'~ , . . ., , . ., ,, ' ,;. j, , . ~ ,: ,. .
2~:37B96 ~A492 --10~
benzazepines and the like employing the calcium channel blockex in amounts as indicated i~ the PDR
such as in an amount of from about 1 to about 1000 mg per day. Such a combination would be at a weight ratio of thromboxane antagonist to calcium channel blocker of from about 1:10 to about 10:1.
- The thrombo~ane receptor antagonist may also be employed in combination with direct vasodilators such as hydrala~ine or minoxidil.
` ~Q~g6 :
~A492 ~he following ~xamples represent preferred embodiment~ of the pr~sent invention.
Example 1 An injectable solution of ~hromboxane A2 receptor antagonist for intravenous use in treating hypertension is produced as follows:
[lS;[la,2a(5Z),3a,4a]]-7-[3~[[2-~phenylamino)carbonyllhydra7.ino]-methyl]-7-oxabicyclo[2.~.l]hept-2-yl~-5-heptenoic acid (SQ 29,548)2500 mg Methyl paraben S mg - Propyl paraben l mg 15 Sodium chloride 25 g Water for injection gs. 5 1.
: The thromboxane A2 receptor antagonist,preservatives and sodium chloride are dissolved in 3 liters of water for injection and then the volume is brought up to 5 liters. The solution is filtered through a sterile filter and aseptically filled into pre~terilized vials which are then closed with presterilized rubber cloaures. Each vial contains a concentration of 75 mg of active ingredient per 150 ml of solution.
Exam~le 2 An injectable for use in treating hypertension is prepared as described in Example 1 except that the thromboxane A~ receptor antagonist employed is [lS-[la,2a(5Z),3a(1E,3R,4S),4a]] 7-[3-.~ ' .
. ~ .. . . . . .
. : . . . ~ , ; -.. . .. .. , . ~ . , . ;
~37l~6 (3-hydroxy-4-phenyl-1-pentenyl)-7-oxabicyclo-[2.2.1]hept-2-yl]-5-heptenoic acid (SQ 28,668).
ExamPle 3 An injectable solution of thromboxane A2 receptor antagonist for use in treating hypertension containing [lS-[1~, 2a ( 5Z ), 3a, 4a ] ] -7-[3-[[[[(1-oxoheptyl)amino]acetyl]amino]methyl]-7-oxabicyclo[2.2.1]-hept-2-yl]-5-heptenoic ac:id (SQ
30,741) as the thromboxane A2 receptor antagonist is prepared as described in Example 1.
Example 4 An injectable for use in treating hyperten~ion is prepared as described in E,xample 1 except that the thromboxane A2 receptor antagonist employed is [lS-[la,2~(Z),3a,4a]]-7-[3-[[[[(4-cyclohexyl-1-oxobutyl)amino]acetyl]amino]methyl]-7-oxabicyclo[2.2.1]hept-2-yl]-5-heptenoic acid.
Example 5 , A thromboxane A2 antagonist formulation suitable ~or oral administration for use in ;; treating hypertension is set out below.
1000 tablets each containing 400 mg of thromboxane A2 recepkor antagonist are produced from the following ingredie~ts.
. . . .
[lS-[la,2a(5Z),3a,4~]]~7-[3-[[[[(1-Oxoh~ptyl)amino]acetyl]amino]methyl]-7-oxabicyclo[2.2.1]hept-2-yl]-5-heptenoic acid (SQ 30,741) 400 g Corn Starch 50 g Gelatin 7.5 g :' .
Avicel (microcrystalline cellulose) 2S g Magnesium stearate 2.5 g The thromboxane A2 receptor antagonist and corn starch are admi~ed with an aqueous solution of the gelatin. The mixture is dried and ground to a fine powder. The Avicel and then the magnesium stearate axe admixed with the granulation. This is then compressed in a tablet to form 1000 tablets each containing 400 mg of active ingredient.
Example 6 A thromboxane A2 antagonist tablet : formulation for use in treating hypertension is prepared as described in Example 5 except that SQ
29,548 is employed as ~he thromboxane A2 r.eceptor antagonist in place of SQ 30,741.
.~ , Exam~e 7 A thromboxane A2 antagonist tablet ; formulation for use in treating hypertension is prepared as described in Example 5 except that SQ
28,668 is employed in place of SQ 30,741.
It will also be appreciated that the above thro~boxane A2 antago~ist formulations may also include a beta blocker such a~ propranolol or atenolol, an ACE i~libitor such a~ enalapril, lisinopril, zofenopril, fosinopril or SQ 29,852, an endopeptidase inhibitor or human ANF 99-126, a diuretic or a vasodilator.
~.
.. . .. .
'',.,' ' ,,., '" '' , : , ` 2~7139Ç~
Example 8 A thromboxane receptor A2 antagonist-calcium channel blocker formulat:Lon suitable for oral administration for treating h~pertension is set out below.
1000 tablets each contain:Lng 400 mg of thrombo~ane A2 antagonist and 100 mg diltiazem are produced from the following ingredients.
[lS-[la,2a(5Z),3a,4a]]-7-[3-~[[[(1-Oxoheptyl)amino]acetyl]amino~methyl]-7-oxabicyclo[2.2.1] hept-2-yl]-5-heptenoic acid (SQ 30,741) 400 g Diltiazem 100 g 15 Corn starch 50 g Gelatin 7.5 g Avicel (microcrystalline cellulose) 25 g Magnesium stearate 2.5 g The thromboxane antagonist, diltiazem and corn starch are admi~ed with an aqueous solution of ; the gelatin. The mixture is dried and ground to a fine powder. The ~vicel and then the magnesium stearate are admixed with the granulation. This is then compressed in a tablet to form 1000 tablets each containing 500 mg of active ingredients.
Example 9 An injectable solution for use in administexing calcium channel blocker and thromboxane A2 receptor antagonist is produced as follows:
.' .
~ , .
` 2~7~6 [lS-[1~2~(5Z),3a,4~]]-7-[3-[[2-(phenylamino)carbonyl]hydrazino]-methyl]-7-oxabicyclo[2.2.1]hept-2-yl]-5-heptenoic acid (SQ 29,548) 5 or SQ30,741 2500 mg Nifedipine or diltiazem2500 mg : Methyl paraben 5 mg Propyl paraben 1 mg Sodium chloride 25 g :. 10 Water for injection qs. 5 1.
The calcium channel blocker, thromboxane A~
antagonist, preservatives and sodium chloride are :dissolved in 3 liters of water for injection and then the volume is brought up to 5 liters. The solution is filtered through a sterile filter and aseptically filled into presterilized vials which are then closed with presterilized rubber closures.
Each vial contains a concentration of 75 mg of active ingredient per 150 ml of solution.
ExamPle 10 ~ n injectable for use in treating hypertension is prepared as described in Example 9 25 except that the thromboxane ~2 antagonist employed . i~ the phenoxyalkyl carboxylic acid 4-[2-(benzene-sulf~mido)ethyl]phenoxyacetic acid, disclosed in U. S. Patent No. 4,258,058.
Example 11 An injectable for use in trPating hypertension is prepared as described in Example 9 . .
.. .
: :
,' ' '`'~' '' .' ' ': '. . 1'.'.'. .'. . '. . ' ' ` '' ' "'"' ;' .
. . . :' - \~
Z~78~6 EA~92 except that the thromboxan2 A2 antagonist employed is [lS-[la,2~(Z),3~,4~]~-7-[3-[[[[(4-cyclohe~yl~
l-oxobutyl)amino]acetyl]amino]methyl]-7-oxabicyclo-[2.2.1]hept-2-yl]~5-heptenolc acid.
i Example 11 ~ -1000 tablets each containing 200 mg of SQ 32,324 and 400 mg SQ 30,741 are produced from the following ingredients:
(d-cls)-3-(acetyloxy)-1,3,4,5-tetrahydro-4-(4-methoxyphenyl)-1-[2-(methylamino)ethyl]-6-(trifluoro-methyl)-2H-1-benzazepin-2-one, monohydrochloride salt (SQ 32,324) 200g SQ 30,741 400g Lactose lOOg Avicel 150g Corn starch 50g 20 Magnesium stearate 5g .
SQ 32,324, SQ 30,741, lactose and Avicel are admixed, then blended with the corn starch.
Magnesium stearate is added. The dry mixture is compressed in a tablet press to form 1000 505 mg tablets each containing 200 mg of active ingredient.
The tablets are coated with a solution of Methocel E 15 (methyl cellulose) including as a color a lake ,; containing yellow #~. The resulting tablets are useful in treating hypertension.
~' :
, ' .
.'' , :` .
, .,',~, -.. , 7~ 6 Example 12 Two piece #l gelatin capsules each containing 50 mg of captopril an~l 250 mg of SQ
30,741 are filled with a mixture of the following ingredients:
SQ 30,7`41250 mg Captopril 50 mg Magnesium stearate 7 mg 10 UsP lactose 193 mg.
The resulting capsules are useful in treating hypertension.
lS Example 13 An inject~ble solution for u~e in treating hypertension is produced as follows:
(d-cis3~3-(acetyloxy)-1-[2-dimethyl-amino)ethyl]-1,3,4,5-tetrahydro-4-(4-methoxyphenyl) 6-~txifluoromethyl)-2H-1-benzazepin-2-one, monohydro-chloride (SQ 31,765) 500 mg SQ 30,741 25Q mg 2~ Me~hyl paraben 5 mg Propyl paraben 1 mg.
Sodium chloride 25 g Water for injection qs. 5 1.
SQ 31,765, SQ 30,74~, preservatives and sodium chloride are dissolved in 3 liters of water ., ., : , ,:
Z0~7B96 H~492 -~
for injection and then the volumle is brought ~p to 5 liters. The solu~ion is filt~rled through a sterile filter and aseptically filled into presterilized vials which are th,_n closed with .. 5 presterilized rubber closures. Each vial contains 5 ml of solutio~ in a c:oncentration of 100 mg of active ingredient per ml of solution for injection.
Example 14 A thromboxane antagonist-beta blocker ::
formulation suitable for oral administration for treating hypertension prepared as described in Example 1, is set out below.
1000 tablets each containing 400 mg of ; 15 thromboxane antagonist and 40 mg nadolol are produced from the following ingredients.
SQ 30,741 400 g Nadolol 40 g 20 Corn star~h 50 g Gelatin 7-5g '. Avicel (microcrystalline cellulose) 25 g Magnesium stearate 2.5 g , :
Examle 15 ` The following experiment demonstrates that a thromboxane receptor antagonist decreases blood pressure.
A thromboxane receptor antagonist ; 30 [lS-[la,2a(5Z),3~,4~]]-7-[3-~[[[(1-oxoheptyl)- :
~ amino]acetyl]amino]methyl~-7-oxabicyclo-: ' : ' ~
~, .
:.'.
.- . . . .
~C~
--19 - .
[2.2.1~hept-2-yl] 5-heptenoic acid (SQ), or placebo (PLA) was given to 3 groups of 12 healthy human subjects (8 per group received SQ and 4 PLA). SQ was given as a single 50 mg IV bolus followed by an infusion of 3, 6 or 12 mg/hr for 48 hours. ~ean pharmacodynamic (PD) parameters at 48 hours were:
% Decrease Max. % ~% IncreasePlatelet Bleeding Aggregation Dose Diastolic BPTime low hiqh PLA -14~3 22~15 -9+11 -7~6 3 -20~3 156$55* 98~4* 89~17*
6 -18+3 111~19~ 100+0* 76i7*
12 ~28+~* 122i34~ lOOiO~ 88il6*
(*p<O.05 vs. PLA) SQ specifically inhibited TXA2-mediated platelet aggregation ex vivo at low and high agonist (U46619) concentrations. Mean platelet TXA2 receptor (R) affinity and density measured ex vivo were not changed. SQ increased template bleeding time when R occupancy was ~99% but not when R occupancy was ~70%.
From the above, it is seen that the thromboxane receptor antagonist reduced diastolic blood prescure.
:
,, .:
~..
~ H2 )rl ~~H~Ra and including all stereoisomers thereof, wherlein A is C~=CH or (CH2)2; m1 is 1 to 8; n1 is 0 ,! to 5, Ra is H or lower alkyl, and Ra is lower alkyl, aryl, aralkyl, lower alkoxy, aralkoxy or O
a 20 wherein R2a is lower alkyl, aryl, aralkyl, alkoxy, ~` aryloxy, aralkoxy, alkylamino, arylamino or aralkylamino.
:~ The 7-oxabicycloheptane prostaglandin analogs suitable for use herein, as disclosed in 25 U.S. Patent No. 4,537,981, have the formula ~2-A-(C~2)m -X
B-CH~Y
o OH
.
.,~
,.`~
.
, . ~ . .
., . :. . ' ' ' ' ' ' ' ' ' ' ' ' ' . . " ', .;`.~': . . , : - ' . ,, , ~ : ,. .: .. . . . :; ;:
.
~ 2t~ 7~96 ~:
_5_ and including all stereoisomers th~reof, wherein A
and B may be the same or differe~nt and A is cH=CH or (c~2)2; B is CH=CH, c--c or (~H2)2; m1 is 1 to 8;
X is OH;
N~-N
c~ il N--N
: 10 CO2Ra wherein Ra is H or lower alkyl; or ' O :
:: It CNH-Z
. wherein Z is H, lower alkyl, aryl, SO2-Q~
; (with Q1 being lower alkyl or aryl), -I~ .
C-Q , " 1 ,~ .
or O~ wherein ~ is H, and Y is alkyl, ..
;. substituted alkyl; aryl-lower alkyl; alkenyl; , ~;
alkynyl, aryl; pyridyl; substituted pyridyl; ~-20 pyridyl-lower alkyl; thienyl, substituted thienyl; :~.
thienyl-lower alkyl; cycloalkyl; cycloalkylalkyl;
substituted cycloalkylalkyl; or phenoxymethyl.
. Preferred exc~mples of thromboxane A2 receptor antagonists which may be employed herein 25 include the 7-oxabicycloheptane compounds disclosed ~ :
in U.S. Patsnt No. 4,537,981, especially, [lS-[la,2a(5Z),3a(1E,3R,~S~,4a]]-7-~3-(3-hydroxy-4-phenyl-l-pentenyl)-7-oxabicyclo-[2.2.1]hept-2-yl]-5-heptenoic acid; the 7-oxabicycloheptane :~
substituted amino-prostaglandin analog~ disclosed in U.S. Patent No. 4,416,896, especially, ~lS- :~
: [ la, 2~,(5Z),3~, 4a ~ ] - 7- [ 3 - ~ [ 2-(phenyl~mino)carbonyl]
hydrazino]methyl]-7-oxabicyclo[2.2.1]hept-2-yl]-5-. ~'.
.,~. - . .
. . .
.. . . . ,, .. . , . ~ .,. . . ,. ., :. . . . , .~- .. .
heptenoic acid; the 7-oxabicycloheptane substituted diamide prostaglandin analogs di~closed in U.S. ~.
Patent No. 4,663,336, especially, [1S-[1~,2al5Z), 3a,4~]]-7-[3-[[[[(1 oxoheptyl)amino~acetyl]amino]
; 5 methyl]-7-oxabicyclo[2.2.1]hept-.2-yl~-5-heptenoic acid and the corresponding tetrazole, and [lS-[la,2a(Z),3a,4~]]-7-[3-[[[[(4-cyclohexyl-1-; oxobutyl)amino]acetyl]amino~methyl]-7-oxabicyclo~
[2.2.1Jhept-2-yl]-5-heptenoic acid.
Examples of other such thromboxane A2 antagonists suitable for use herein include but are not limited to the phenoxyalkyl carboxylic aci.ds disclosed in U. S. Patent No. 4,258,058 to Witte et al, especially 4-[2-(benzenesulfamido)ethyl]phenoxy-: 15 acetic acid, (BM 13,177 - Boehringer Mannheim), the sulphonamidophenyl carboxylic acids disclosed in U. S. Patent No. 4,443,~77 to Witte et al, especially 4-[2-(4-chlorobenzenesulfonamido)-, ethyl]phenylacetic acid, ~BM 13,505, Boehringer Mannheim) the arylthioalkylphenyl carboxylic acids disclosed in U. S. Patent No. 4,752,676 espscially 4-(3-((4-chlorophenyl)sulfonyl)propyl)benzeneacetic acid, (E)-5-[~[(pyridinyl)[3-(trifluoro-methyl)phenyl]methylene]amino]oxy]pentanoic acid also referred to as R68,070 - Janssen Research Laboratories, 3-[1-(4-chlorophenylmethyl)-5-fluoro-3-~ethylindol-2-yl]-2,2-dimethylpropanoic acid [(L-655240 Merck-Frosst) Eur. J. Pharmacol.
135(2):193, 17 Mar. 87], 5(Z)-7-([2,4,5-cis]-4-(2-hydroxyphenylj-2-trifluoromethyl-1,3-dioxan-5-yljheptenoic acid (ICI 185282, Brit. J.
:: Pharmacol 90 (Proc. Suppl):228 P-Abs., Mar. 87), 5(Z)-7 [2,2-dimethyl-4-phenyl-1,3-dioxan-cis-5-yl3-, . . .
. ~ , . . ~
.' ' ' ',: . : " , :
' ., ' ' ., ',:. . ' . ' ' ;
.... ~
. . . . .. .
HA~92 heptenoic acid (ICI 159995~ Brit. J. Pharmacol. 86 (Proc. suppl):808 P-Abs., Dec. 85~, N,N'-bis~7-(3-chlorobenzeneaminosulfonyl)-1,2,3,4- -tetrahydro-isoquinolyl]disulfonylimide (SKF 88046, ~ 5 Pharmacologist 25(3):116 Abs, 117 Abs, Aug. 83), ; [la(Z)-2~,5a]-(+~-7-[5-[[(1,1'-biphenyl)-4-yl]-methoxy]-2-(4-morpholinyl)-3-oxocyclopentyl]-4-heptenoic acid (A~ 23848 - Glaxo, Circulation 72(6):1208, Dec. 85, levallorphan allyl bromide (CN 32,191, Sanofi, Life Sci. 31 (20-21):2261, 15 ,~
; ~ov. 82), (Z,2-endo-3-oxo)-7-(3 acetyl-2-bicyclo-[2.2.1]heptyl-5-hepta-3Z-enoic acid, 4-phenylthiosemicarbazone (EP092 - Univ.
Edinburgh, Brit, J. Pharmacol. 84(3):595, Mar. 85).
The disclosures of the above-mentioned patents are incorporated herein by reference.
In carrying out the method of the present invention, the thromboxane A2 receptor antagonist may be administered systemically, such as orally or parenterally, to mammalian species, such as monkeys, dogs, cats, rats, humans, etc.
The thromboxane A2 receptor antagonist may be incorporated in a conventional dosage form, such as a tablet, capsule, elixir or injectable.
The above dosage forms will also include the necessary carrier material, excipient, lubricant, bufer, antibacterial, bulking agent (such as mannitol), anti-oxidants (ascorbic acid or sodium bisulfite) or the like. Oral dosage forms are preferred, although parenteral forms are quite satisfactory as well.
With regard to such systemic formulations, single or divided doses of rom about 0.5 to about . ' .
: .
2~37B96 ~A492 2500 mg, preferably from about 5 to 500 mg one to six times daily, may be administered in systemic dosage forms as described above for a prolonged period, that is, for as long as hypertension continues. Sustained release forms of such ; formulations which may provide such amounts biweekly, weekly, monthly and the lik~ may also be employed.
The thromboxane antagonist can al90 be formulated with a diuretic for the treatment of hyper~ension. A combination product comprising thromboxane antagonist and a diuretic can be a~ministered in an effective amount which comprises a totally daily dosage of about 30 to 600 mg, preferably about 30 to 330 mg of thromboxane antagonist, and about 15 to 300 mg preferably about 15 to 200 of the diuretic, to a mammalian species in need thereof. Exemplary of the diuretics contemplated for use in combination with a compound of this invention are the thiazide diuretics, e.g., chlorothiazide, hydrochlorothiazide, flumethiazide, hydroflumethiazide, bendroflumethiazide, methylclo~hiazide, trichloromethiazide, polythiazide or benzthiazide as well as ethacrynic acid, tricrynafen, chlorothalidone, furosamide, musolimine, bumetanide, triamterene, amiloride and spironolactone and salts of such compounds.
In treating hyperten~ion, the thromboxane receptor antagonists may be administered in combination with an angiotensin-converting enzyme (ACE) inhibitor such as captopril, zofenopril, - fosinopril, enalapril, lisinopril, (S)~1-[6-amino-~ .
- :," ~, " , . ,:
, , : ; , .
2~ 396 _ 9~
2-[[hydroxy(4-phenylbutyl)phosphinyl]oxy]-1-oxohexyl]-L-proline (SQ 29,852) etc. employing the ACE inhibitor in an amount as indicated in the Physicians Desk Reference (PDR), for example, from about 5 to about 350 mg per day. Such combination would be at a weight ratio of thromboxane antago~ist to ACE i~libitor of from about 1:1~ t~ about 10:1.
; The thromboxane receptor antagonists can ; 10 also be administered in combination with a neutral endopeptidase inhibitor or with human ANF 99 -126 in treating hypertension. Such combination would contain the ~hromboxane antagonist at from about 1 to about 500 mg per day and an endopepti-dase inhibitor of from about 1 to about 100 mg per kg of body weight or the human ANF 99 - 126 at from about 0.001 to about 0.1 mg per kg of body weight.
In addition, in treating hypertension, the thromboxane receptor antagonists may be employed in combination with a beta blocker such as propranolol, ~adolol, timolol maleate, metoprolol tartrate, labetalol hydrochloride and the like employing ~he beta blocker in amounts as indicated in the PDR such as in an amount of from about 5 to about 350 mg per day. Such a combination would be at a weight ratio of thromboxane antagonist to beta blocker of from about l:lO to about 10:1.
The thromboxane receptor antagonist, in treating hypertension, may also be used in combination with a calcium channel blocker such as dihydropyridines such as niedipine, nitrendipine, nimodipine, phenylalkylamines such as verapamil, benzothiazepines such as diltiazem and ., .
.. , ' '' ~ . . . ., ;. . : . .. ..
'~ , . . ., , . ., ,, ' ,;. j, , . ~ ,: ,. .
2~:37B96 ~A492 --10~
benzazepines and the like employing the calcium channel blockex in amounts as indicated i~ the PDR
such as in an amount of from about 1 to about 1000 mg per day. Such a combination would be at a weight ratio of thromboxane antagonist to calcium channel blocker of from about 1:10 to about 10:1.
- The thrombo~ane receptor antagonist may also be employed in combination with direct vasodilators such as hydrala~ine or minoxidil.
` ~Q~g6 :
~A492 ~he following ~xamples represent preferred embodiment~ of the pr~sent invention.
Example 1 An injectable solution of ~hromboxane A2 receptor antagonist for intravenous use in treating hypertension is produced as follows:
[lS;[la,2a(5Z),3a,4a]]-7-[3~[[2-~phenylamino)carbonyllhydra7.ino]-methyl]-7-oxabicyclo[2.~.l]hept-2-yl~-5-heptenoic acid (SQ 29,548)2500 mg Methyl paraben S mg - Propyl paraben l mg 15 Sodium chloride 25 g Water for injection gs. 5 1.
: The thromboxane A2 receptor antagonist,preservatives and sodium chloride are dissolved in 3 liters of water for injection and then the volume is brought up to 5 liters. The solution is filtered through a sterile filter and aseptically filled into pre~terilized vials which are then closed with presterilized rubber cloaures. Each vial contains a concentration of 75 mg of active ingredient per 150 ml of solution.
Exam~le 2 An injectable for use in treating hypertension is prepared as described in Example 1 except that the thromboxane A~ receptor antagonist employed is [lS-[la,2a(5Z),3a(1E,3R,4S),4a]] 7-[3-.~ ' .
. ~ .. . . . . .
. : . . . ~ , ; -.. . .. .. , . ~ . , . ;
~37l~6 (3-hydroxy-4-phenyl-1-pentenyl)-7-oxabicyclo-[2.2.1]hept-2-yl]-5-heptenoic acid (SQ 28,668).
ExamPle 3 An injectable solution of thromboxane A2 receptor antagonist for use in treating hypertension containing [lS-[1~, 2a ( 5Z ), 3a, 4a ] ] -7-[3-[[[[(1-oxoheptyl)amino]acetyl]amino]methyl]-7-oxabicyclo[2.2.1]-hept-2-yl]-5-heptenoic ac:id (SQ
30,741) as the thromboxane A2 receptor antagonist is prepared as described in Example 1.
Example 4 An injectable for use in treating hyperten~ion is prepared as described in E,xample 1 except that the thromboxane A2 receptor antagonist employed is [lS-[la,2~(Z),3a,4a]]-7-[3-[[[[(4-cyclohexyl-1-oxobutyl)amino]acetyl]amino]methyl]-7-oxabicyclo[2.2.1]hept-2-yl]-5-heptenoic acid.
Example 5 , A thromboxane A2 antagonist formulation suitable ~or oral administration for use in ;; treating hypertension is set out below.
1000 tablets each containing 400 mg of thromboxane A2 recepkor antagonist are produced from the following ingredie~ts.
. . . .
[lS-[la,2a(5Z),3a,4~]]~7-[3-[[[[(1-Oxoh~ptyl)amino]acetyl]amino]methyl]-7-oxabicyclo[2.2.1]hept-2-yl]-5-heptenoic acid (SQ 30,741) 400 g Corn Starch 50 g Gelatin 7.5 g :' .
Avicel (microcrystalline cellulose) 2S g Magnesium stearate 2.5 g The thromboxane A2 receptor antagonist and corn starch are admi~ed with an aqueous solution of the gelatin. The mixture is dried and ground to a fine powder. The Avicel and then the magnesium stearate axe admixed with the granulation. This is then compressed in a tablet to form 1000 tablets each containing 400 mg of active ingredient.
Example 6 A thromboxane A2 antagonist tablet : formulation for use in treating hypertension is prepared as described in Example 5 except that SQ
29,548 is employed as ~he thromboxane A2 r.eceptor antagonist in place of SQ 30,741.
.~ , Exam~e 7 A thromboxane A2 antagonist tablet ; formulation for use in treating hypertension is prepared as described in Example 5 except that SQ
28,668 is employed in place of SQ 30,741.
It will also be appreciated that the above thro~boxane A2 antago~ist formulations may also include a beta blocker such a~ propranolol or atenolol, an ACE i~libitor such a~ enalapril, lisinopril, zofenopril, fosinopril or SQ 29,852, an endopeptidase inhibitor or human ANF 99-126, a diuretic or a vasodilator.
~.
.. . .. .
'',.,' ' ,,., '" '' , : , ` 2~7139Ç~
Example 8 A thromboxane receptor A2 antagonist-calcium channel blocker formulat:Lon suitable for oral administration for treating h~pertension is set out below.
1000 tablets each contain:Lng 400 mg of thrombo~ane A2 antagonist and 100 mg diltiazem are produced from the following ingredients.
[lS-[la,2a(5Z),3a,4a]]-7-[3-~[[[(1-Oxoheptyl)amino]acetyl]amino~methyl]-7-oxabicyclo[2.2.1] hept-2-yl]-5-heptenoic acid (SQ 30,741) 400 g Diltiazem 100 g 15 Corn starch 50 g Gelatin 7.5 g Avicel (microcrystalline cellulose) 25 g Magnesium stearate 2.5 g The thromboxane antagonist, diltiazem and corn starch are admi~ed with an aqueous solution of ; the gelatin. The mixture is dried and ground to a fine powder. The ~vicel and then the magnesium stearate are admixed with the granulation. This is then compressed in a tablet to form 1000 tablets each containing 500 mg of active ingredients.
Example 9 An injectable solution for use in administexing calcium channel blocker and thromboxane A2 receptor antagonist is produced as follows:
.' .
~ , .
` 2~7~6 [lS-[1~2~(5Z),3a,4~]]-7-[3-[[2-(phenylamino)carbonyl]hydrazino]-methyl]-7-oxabicyclo[2.2.1]hept-2-yl]-5-heptenoic acid (SQ 29,548) 5 or SQ30,741 2500 mg Nifedipine or diltiazem2500 mg : Methyl paraben 5 mg Propyl paraben 1 mg Sodium chloride 25 g :. 10 Water for injection qs. 5 1.
The calcium channel blocker, thromboxane A~
antagonist, preservatives and sodium chloride are :dissolved in 3 liters of water for injection and then the volume is brought up to 5 liters. The solution is filtered through a sterile filter and aseptically filled into presterilized vials which are then closed with presterilized rubber closures.
Each vial contains a concentration of 75 mg of active ingredient per 150 ml of solution.
ExamPle 10 ~ n injectable for use in treating hypertension is prepared as described in Example 9 25 except that the thromboxane ~2 antagonist employed . i~ the phenoxyalkyl carboxylic acid 4-[2-(benzene-sulf~mido)ethyl]phenoxyacetic acid, disclosed in U. S. Patent No. 4,258,058.
Example 11 An injectable for use in trPating hypertension is prepared as described in Example 9 . .
.. .
: :
,' ' '`'~' '' .' ' ': '. . 1'.'.'. .'. . '. . ' ' ` '' ' "'"' ;' .
. . . :' - \~
Z~78~6 EA~92 except that the thromboxan2 A2 antagonist employed is [lS-[la,2~(Z),3~,4~]~-7-[3-[[[[(4-cyclohe~yl~
l-oxobutyl)amino]acetyl]amino]methyl]-7-oxabicyclo-[2.2.1]hept-2-yl]~5-heptenolc acid.
i Example 11 ~ -1000 tablets each containing 200 mg of SQ 32,324 and 400 mg SQ 30,741 are produced from the following ingredients:
(d-cls)-3-(acetyloxy)-1,3,4,5-tetrahydro-4-(4-methoxyphenyl)-1-[2-(methylamino)ethyl]-6-(trifluoro-methyl)-2H-1-benzazepin-2-one, monohydrochloride salt (SQ 32,324) 200g SQ 30,741 400g Lactose lOOg Avicel 150g Corn starch 50g 20 Magnesium stearate 5g .
SQ 32,324, SQ 30,741, lactose and Avicel are admixed, then blended with the corn starch.
Magnesium stearate is added. The dry mixture is compressed in a tablet press to form 1000 505 mg tablets each containing 200 mg of active ingredient.
The tablets are coated with a solution of Methocel E 15 (methyl cellulose) including as a color a lake ,; containing yellow #~. The resulting tablets are useful in treating hypertension.
~' :
, ' .
.'' , :` .
, .,',~, -.. , 7~ 6 Example 12 Two piece #l gelatin capsules each containing 50 mg of captopril an~l 250 mg of SQ
30,741 are filled with a mixture of the following ingredients:
SQ 30,7`41250 mg Captopril 50 mg Magnesium stearate 7 mg 10 UsP lactose 193 mg.
The resulting capsules are useful in treating hypertension.
lS Example 13 An inject~ble solution for u~e in treating hypertension is produced as follows:
(d-cis3~3-(acetyloxy)-1-[2-dimethyl-amino)ethyl]-1,3,4,5-tetrahydro-4-(4-methoxyphenyl) 6-~txifluoromethyl)-2H-1-benzazepin-2-one, monohydro-chloride (SQ 31,765) 500 mg SQ 30,741 25Q mg 2~ Me~hyl paraben 5 mg Propyl paraben 1 mg.
Sodium chloride 25 g Water for injection qs. 5 1.
SQ 31,765, SQ 30,74~, preservatives and sodium chloride are dissolved in 3 liters of water ., ., : , ,:
Z0~7B96 H~492 -~
for injection and then the volumle is brought ~p to 5 liters. The solu~ion is filt~rled through a sterile filter and aseptically filled into presterilized vials which are th,_n closed with .. 5 presterilized rubber closures. Each vial contains 5 ml of solutio~ in a c:oncentration of 100 mg of active ingredient per ml of solution for injection.
Example 14 A thromboxane antagonist-beta blocker ::
formulation suitable for oral administration for treating hypertension prepared as described in Example 1, is set out below.
1000 tablets each containing 400 mg of ; 15 thromboxane antagonist and 40 mg nadolol are produced from the following ingredients.
SQ 30,741 400 g Nadolol 40 g 20 Corn star~h 50 g Gelatin 7-5g '. Avicel (microcrystalline cellulose) 25 g Magnesium stearate 2.5 g , :
Examle 15 ` The following experiment demonstrates that a thromboxane receptor antagonist decreases blood pressure.
A thromboxane receptor antagonist ; 30 [lS-[la,2a(5Z),3~,4~]]-7-[3-~[[[(1-oxoheptyl)- :
~ amino]acetyl]amino]methyl~-7-oxabicyclo-: ' : ' ~
~, .
:.'.
.- . . . .
~C~
--19 - .
[2.2.1~hept-2-yl] 5-heptenoic acid (SQ), or placebo (PLA) was given to 3 groups of 12 healthy human subjects (8 per group received SQ and 4 PLA). SQ was given as a single 50 mg IV bolus followed by an infusion of 3, 6 or 12 mg/hr for 48 hours. ~ean pharmacodynamic (PD) parameters at 48 hours were:
% Decrease Max. % ~% IncreasePlatelet Bleeding Aggregation Dose Diastolic BPTime low hiqh PLA -14~3 22~15 -9+11 -7~6 3 -20~3 156$55* 98~4* 89~17*
6 -18+3 111~19~ 100+0* 76i7*
12 ~28+~* 122i34~ lOOiO~ 88il6*
(*p<O.05 vs. PLA) SQ specifically inhibited TXA2-mediated platelet aggregation ex vivo at low and high agonist (U46619) concentrations. Mean platelet TXA2 receptor (R) affinity and density measured ex vivo were not changed. SQ increased template bleeding time when R occupancy was ~99% but not when R occupancy was ~70%.
From the above, it is seen that the thromboxane receptor antagonist reduced diastolic blood prescure.
:
,, .:
~..
Claims (23)
1. A method for treating hypertension in a mammalian species, which comprises administering to a mammalian species in need of such treatment a blood pressure lowering effective amount of a thromboxane A2 receptor antagonist.
2. The method as defined in Claim 1 wherein the thromboxane A2 receptor antagonist is a 7-oxabicycloheptane prostaglandin analog.
3. The method as defined in Claim 2 wherein the 7-oxabicycloheptane prostaglandin analog is a 7-oxabicycloheptane substituted diamide prostaglandin analog or a 7-oxabicycloheptane substituted amino prostaglandin analog.
4. The method as defined in Claim 2 wherein the 7-oxabicycloheptane prostaglandin analog has the formula and including all stereoisomers thereof, wherein A and B may be the same or different and A
is CH=CH or (CH2)2; B is CH=CH, C?C or (CH2)2; m1 is 1 to 8; X is OH;
;
CO2Ra wherein Ra is H or lower alkyl; or ?NH-Z
wherein Z is H, lower alkyl, aryl, SO2-Q1 (with Q1 being lower alkyl or aryl), ?-Q1, or OR? wherein R2 is H, and Y is alkyl; substituted alkyl; aryl-lower alkyl; alkenyl; alkynyl, aryl;
pyridyl; substituted pyridyl; pyridyl-lower alkyl;
thienyl, substituted thienyl; thienyl-lower alkyl;
cycloalkyl; cycloalkylalkyl; substituted cycloalkylalkyl; or phenoxymethyl.
is CH=CH or (CH2)2; B is CH=CH, C?C or (CH2)2; m1 is 1 to 8; X is OH;
;
CO2Ra wherein Ra is H or lower alkyl; or ?NH-Z
wherein Z is H, lower alkyl, aryl, SO2-Q1 (with Q1 being lower alkyl or aryl), ?-Q1, or OR? wherein R2 is H, and Y is alkyl; substituted alkyl; aryl-lower alkyl; alkenyl; alkynyl, aryl;
pyridyl; substituted pyridyl; pyridyl-lower alkyl;
thienyl, substituted thienyl; thienyl-lower alkyl;
cycloalkyl; cycloalkylalkyl; substituted cycloalkylalkyl; or phenoxymethyl.
5. The method as defined in Claim 3 wherein the 7-oxabicycloheptane substituted diamide prostaglandin analog has the formula including all stereoisomers thereof, wherein m is 0 to 4; A is -CH=CH- or -CH2-CH2-; n is 1 to 5; Q
is -CH=CH-, -CH2, , , .
or a single bond; R is CO2H, CO2alkyl, CO2 alkali metal, CO2polyhydroxyamine salt, -CH2OH, or -?R4R5 wherein R4 and R5 are the same or different and are H, lower alkyl, hydroxy, lower alkoxy or aryl at least one of R4 and R5 being other than hydroxy and lower alkoxy; p is 1 to 4; R1 is H or lower alkyl; q is 1 to 12; R2 is H or lower alkyl; and R3 is H, lower alkyl, lower alkenyl, lower alkynyl, aryl, arylalkyl, lower alkoxy, arylalkyloxy, aryloxy, amino, alkylamino, arylalkylamino, arylamino, lower alkyl-, aryl-, arylalkyl-, aryl--alkyl-, alkyl--alkyl-, arylalkyl--alkyl (wherein n' is 0, 1 or 2), alkylaminoalkyl, arylaminoalkyl, arylalkylaminoalkyl, alkoxyalkyl, aryloxyalkyl or arylalkoxyalkyl.
is -CH=CH-, -CH2, , , .
or a single bond; R is CO2H, CO2alkyl, CO2 alkali metal, CO2polyhydroxyamine salt, -CH2OH, or -?R4R5 wherein R4 and R5 are the same or different and are H, lower alkyl, hydroxy, lower alkoxy or aryl at least one of R4 and R5 being other than hydroxy and lower alkoxy; p is 1 to 4; R1 is H or lower alkyl; q is 1 to 12; R2 is H or lower alkyl; and R3 is H, lower alkyl, lower alkenyl, lower alkynyl, aryl, arylalkyl, lower alkoxy, arylalkyloxy, aryloxy, amino, alkylamino, arylalkylamino, arylamino, lower alkyl-, aryl-, arylalkyl-, aryl--alkyl-, alkyl--alkyl-, arylalkyl--alkyl (wherein n' is 0, 1 or 2), alkylaminoalkyl, arylaminoalkyl, arylalkylaminoalkyl, alkoxyalkyl, aryloxyalkyl or arylalkoxyalkyl.
6. The method as defined in Claim 3 wherein the 7-oxabicycloheptane substituted amino prostaglandin analog has the formula and including all stereoisomers thereof, wherein A
is CH=CH or (CH2)2; m1 is 1 to 8; n1 is 0 to 5, Ra is H or lower alkyl; and R? is lower alkyl, axyl, aralkyl, lower alkoxy, aralkoxy or -NH-?-R2 wherein R? is lower alkyl, aryl, aralkyl, alkoxy, aryloxy, aralkoxy, alkylamino, arylamino or aralkylamino.
is CH=CH or (CH2)2; m1 is 1 to 8; n1 is 0 to 5, Ra is H or lower alkyl; and R? is lower alkyl, axyl, aralkyl, lower alkoxy, aralkoxy or -NH-?-R2 wherein R? is lower alkyl, aryl, aralkyl, alkoxy, aryloxy, aralkoxy, alkylamino, arylamino or aralkylamino.
7. The method as defined in Claim 1 wherein the thromboxane A2 receptor antagonist is [1S-[1.alpha.,2.alpha.(5Z),3.alpha.(1E,3R,4S),4.alpha.]]-7-[3-(3-hydroxy-4-phenyl-1-pentenyl)-7-oxabicyclo[2.2.1]hept-2-yl]-5-heptenoic acid.
8. The method as defined in Claim 1 wherein the thromboxane A2 receptor antagonist has the name [1S-[1.alpha.,2.alpha.(5Z),3.alpha.,4.alpha.]]-7-[3-[[[[(1-oxoheptyl) amino]acetyl]amino]methyl]-7-oxabicyclo[2.2.1]
hept-2-yl]-5-heptenoic acid or the corresponding tetrazole.
hept-2-yl]-5-heptenoic acid or the corresponding tetrazole.
9. The method as defined in Claim 1 wherein the thromboxane A2 receptor antagonist has the name [1S-[1.alpha.,2.alpha.(Z),3.alpha.,4.alpha.]]-7-[3-[[[[(4-cyclohexyl-1-oxobutyl)amino]acetyl]amino]methyl]-7-oxabicyclo [2.2.1]hept-2-yl]-5-heptenoic acid.
10. The method as defined in Claim 1 wherein the thromboxane A2 receptor antagonist has the name [1S-[1.alpha.,2.alpha.(5Z),3.alpha.,4.alpha.]]-7-[3-[[2-(phenylamino) carbonyl]hydrazino]methyl]-7-oxabicyclo[2.2.1]
hept-2-yl]-5-heptenoic acid.
hept-2-yl]-5-heptenoic acid.
11. The method as defined in Claim 1 wherein the thromboxane A2 receptor antagonist is administered orally or parenterally.
12. The method as defined in Claim 1 wherein the thromboxane receptor antagonist is administered in single or divided doses of from about 0.5 to about 2500 mg/one to four times daily.
13. The method as defined in Claim 1 wherein the thromboxane receptor antagonist is employed in combination with a diuretic.
14. The method as defined in Claim 1 wherein the thromboxane receptor antagonist is employed in combination with an angiotensin-converting enzyme inhibitor.
15. The method as defined in Claim 1 wherein the thromboxane receptor antagonist is employed in combination with a beta-blocker.
16. The method as defined in Claim 1 wherein the thromboxane receptor antagonist is employed in combination with a calcium channel blocker.
17. The method as defined in Claim 1 wherein the thromboxane receptor antagonist is employed in combination with a vasodilator.
18. A new pharmaceutical combination comprising a thromboxane receptor antagonist and a beta blocker.
19. The combination as defined in Claim 18 wherein the beta blocker is nadolol, propranolol, atenolol, timolol, metaprolol, acebutolol or labetalol.
20. A new pharmaceutical combination comprising a thromboxane A2 receptor antagonist and an angiotensin converting enzyme inhibitor.
21. The combination as defined in Claim 20 wherein the angiotensin converting enzyme inhibitor is captopril, enalapril, lisinopril, fosinopril, SQ 29,852 or zofenopril.
22. A new pharmaceutical combination comprising a thromboxane A2 receptor antagonist and an endopeptidase inhibitor or human ANF 99-126.
23. A new pharmaceutical combination comprising a thromboxane A2 receptor antagonist and a diuretic or an endopeptidase inhibitor.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US30673489A | 1989-02-06 | 1989-02-06 | |
US306,734 | 1989-02-06 |
Publications (1)
Publication Number | Publication Date |
---|---|
CA2007896A1 true CA2007896A1 (en) | 1990-08-06 |
Family
ID=23186608
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002007896A Abandoned CA2007896A1 (en) | 1989-02-06 | 1990-01-16 | Method of treating hypertension using a thromboxane a2 receptor antagonist and new combinations |
Country Status (6)
Country | Link |
---|---|
JP (1) | JPH02270826A (en) |
CA (1) | CA2007896A1 (en) |
DE (1) | DE4003392A1 (en) |
FR (1) | FR2642649A1 (en) |
GB (1) | GB2227664A (en) |
IT (1) | IT1238082B (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5021448A (en) * | 1990-02-22 | 1991-06-04 | Ciba-Geigy Corporation | Method of reducing serum uric acid and/or increasing renal uric acid clearance with thromboxane synthetase inhibitor inhibitor and/or thromboxane receptor antagonist |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4537981A (en) * | 1981-11-09 | 1985-08-27 | E. R. Squibb & Sons, Inc. | 7-Oxabicycloheptane and 7-oxabicycloheptene compounds |
US4416896A (en) * | 1982-05-17 | 1983-11-22 | E. R. Squibb & Sons, Inc. | 7-Oxabicyclopheptane substituted amino prostaglandin analogs useful in the treatment of thrombolytic disease |
US4663336A (en) * | 1985-07-01 | 1987-05-05 | E. R. Squibb & Sons, Inc. | 7-oxabicycloheptane substituted diamide and its congener prostaglandin analogs useful in the treatment of thrombotic disease |
-
1990
- 1990-01-16 CA CA002007896A patent/CA2007896A1/en not_active Abandoned
- 1990-01-31 GB GB9002194A patent/GB2227664A/en not_active Withdrawn
- 1990-02-05 DE DE4003392A patent/DE4003392A1/en not_active Withdrawn
- 1990-02-05 IT IT01925690A patent/IT1238082B/en active IP Right Grant
- 1990-02-06 JP JP2027008A patent/JPH02270826A/en active Pending
- 1990-02-06 FR FR9001332A patent/FR2642649A1/fr active Pending
Also Published As
Publication number | Publication date |
---|---|
JPH02270826A (en) | 1990-11-05 |
GB2227664A (en) | 1990-08-08 |
GB9002194D0 (en) | 1990-03-28 |
FR2642649A1 (en) | 1990-08-10 |
IT9019256A0 (en) | 1990-02-05 |
IT9019256A1 (en) | 1990-08-07 |
DE4003392A1 (en) | 1990-08-09 |
IT1238082B (en) | 1993-07-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HU207220B (en) | Process for producing pharmaceutical composition for diminishing enhanced pressure of the pulmonary circulation | |
RU2005102110A (en) | METHOD AND MEDICINE FOR TREATMENT OF SEVERE HEART FAILURE | |
IE60937B1 (en) | Improved flunarizine-containing compositions | |
US4912096A (en) | Method for preventing or treating depression employing an ace inhibitor | |
EP0351755B1 (en) | Combination of a calcium channel blocker and thromboxane a2 receptor antagonist or synthetase inhibitor and method for treating ischemia employing such combination | |
AU626917B2 (en) | Method of inhibiting onset of or treating migraine headache using a thromboxane A2 receptor antagonist | |
EP0381075A2 (en) | Method for treating addiction to a drug of abuse employing an ace inhibitor | |
MXPA01008528A (en) | Therapeutic compositions comprising excess enantiomer. | |
CA2007896A1 (en) | Method of treating hypertension using a thromboxane a2 receptor antagonist and new combinations | |
CA1336168C (en) | Method of preventing or treating toxemia in pregnancy using a thromboxane a_ receptor antagonist | |
EP0309801B1 (en) | Use of thromboxane a2 antagonists for the manufacture of a medicament for improving post-ischemic myocardial dysfunction | |
EP0337697B1 (en) | Use of a thromboxane a2 receptor antagonist for the manufacture of a medicament for treating pulmonary hypertension caused by protamine induced neutralization of hepamin | |
US4558037A (en) | Cardiovascular composition | |
USRE34756E (en) | Excretion of potassium ion by prostanoic acid derivatives | |
EP0474438A1 (en) | Method for preventing or treating cerebrovascular disease employing the ACE-inhibitor ceronapril | |
US5126372A (en) | Excretion of nonprotein nitrogen into the intestine by prostanoic acid derivatives | |
US6201015B1 (en) | Therapeutic method for thrombocytopathy treatment | |
EP0331803A2 (en) | Medicament for inhibiting onset of or treating migraine headaches employing an ace inhibitor | |
AU626829B2 (en) | Method of preventing or reducing platelet loss during extracorporeal circulation using a thromboxane A2 receptor antagonist | |
EP0334264A2 (en) | Pharmaceutical compositions for treating tardive dyskinesia employing an ace inhibitor | |
EP0380956A2 (en) | Method of preventing or treating atherosclerosis using a thromboxane A2 receptor antagonist | |
HU199681B (en) | Process for producing new pharmaceutical composition against hypertension and atonic cardiac decomposition | |
GB2219939A (en) | Use of a thromboxane receptor antagonist in renal diseases and dysfunction |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FZDE | Discontinued | ||
FZDE | Discontinued |
Effective date: 19930717 |